Cargando…
Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study
Secondary hyperparathyroidism in chronic kidney disease poses a major risk factor for vascular calcification and high bone turnover, leading to mineralization defects. The aim was to analyze the effect of active vitamin D and calcimimetic treatment on fibroblast growth factor 23 (FGF23), serum calci...
Autores principales: | Dörr, Katharina, Hödlmoser, Sebastian, Kammer, Michael, Reindl-Schwaighofer, Roman, Lorenz, Matthias, Reiskopf, Bianca, Jagoditsch, Rahel, Marculescu, Rodrig, Oberbauer, Rainer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299083/ https://www.ncbi.nlm.nih.gov/pubmed/35872799 http://dx.doi.org/10.3389/fmed.2022.948177 |
Ejemplares similares
-
Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
por: Dörr, Katharina, et al.
Publicado: (2023) -
Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)
por: Dörr, Katharina, et al.
Publicado: (2019) -
Alkaline Phosphatase in Bone Tumours
por: Chitre, R. G.
Publicado: (1943) -
Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial
por: Oka, Tatsufumi, et al.
Publicado: (2022) -
Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis—a post-hoc analysis of a randomized, controlled trial
por: Dörr, Katharina, et al.
Publicado: (2023)